Current perspective: Bevacizumab in colorectal cancer - A time for reappraisal?

Health economics have unfortunately limited the universal use of bevacizumab, but it is hoped that the future identification of predictive biomarkers may enhance the benefits and thereby improve cost-effectiveness.